Orexo AB publ

📍 Fyrislund, Sweden🗓 Founded 1995👥 116 employees💰 Last funded Apr 2022
Pharmaceutical Manufacturing🌐 orexo.com
Website LinkedIn
Orexo develops improved pharmaceuticals and digital therapies addressing unmet needs within the growing space of substance use disorders and mental health. The products are commercialized by Orexo in the US or via partners worldwide. The main market today is the American market for buprenorphine/naloxone products, where Orexo commercializes its lead product ZUBSOLV® for treatment of opioid use disorder. Total net sales for 2021 amounted to SEK 565 million and the number of employees was 121. Orexo is listed on the Nasdaq Stockholm Mid Cap (ORX) and is available as an ADS on the OTCQX (ORXOY) in the US. The company is headquartered in Uppsala, Sweden, where research and development activities are performed. For more information about Orexo please visit, www.orexo.com. You can also follow Orexo on Twitter, @orexoabpubl, LinkedIn and YouTube.
2
Total investors
0
Early stage
0
Mid stage
1
Late stage
1995
Founded

Investors

2 investors
All
Early stage
Mid stage
Late stage
Investor geography2 countries
Sweden
1
United States
1
Frequently asked questions
Who invested in Orexo AB publ?
Orexo AB publ has 2 investors on record on gritt.io and 1 late-stage investors.
When did Orexo AB publ last raise funding?
The most recent investment in Orexo AB publ recorded on gritt.io was in April 2022.
When was Orexo AB publ founded?
Orexo AB publ was founded in 1995.
What industry is Orexo AB publ in?
Orexo AB publ operates in Pharmaceutical Manufacturing. Find similar Pharmaceutical Manufacturing investors on gritt.io.
Where is Orexo AB publ based?
Orexo AB publ is headquartered in Fyrislund, Sweden.